Ruth Wester

Ruth Wester is a researcher in the Department of Hematology at Erasmus MC, focusing on multiple myeloma and clinical trials in hematologic malignancies. She is actively involved in international collaborations such as the European Myeloma Network (EMN) and the HARMONY Project, contributing to major advancements in staging systems and treatment evaluation frameworks.

Her research interests center on multiple myeloma, clinical trial design, pharmacological treatments (including pomalidomide and dexamethasone), and patient outcomes such as progression-free and overall survival. She contributes to the development of core outcome sets and clinical benefit scales for hematologic malignancies, ensuring patient-centered approaches in oncology research.

The trend in her recent publications highlights a strong focus on evidence-based oncology, with significant contributions to prognostic models (e.g., R2-ISS) and therapeutic evaluation (e.g., ESMO-MCBS:H). Her work bridges clinical research and practical implementation in hematology, with high citation impact and inclusion in clinical guidelines.

She has contributed to several high-impact publications in journals such as Journal of Clinical Oncology, Annals of Oncology, and Haematologica. Notably, her work on the R2-ISS staging system has been cited over 280 times and is referenced in clinical guideline sources. She also authored a doctoral thesis on clinical trials in multiple myeloma, demonstrating deep expertise in trial methodology and treatment outcomes.

Ruth Wester collaborates extensively with leading hematologists and oncologists across Europe. Although no formal advising or grant leadership is mentioned, her role in large consortia like HARMONY and EMN indicates active participation in funded research networks. She is not listed as leading a lab or research team, but her collaborative footprint is substantial.